Markets:

Overview

News

Currencies

International

Treasuries

Pulse Biosciences, Inc - Common Stock (NQ:PLSE)

19.21 +0.56 (+3.00%)

Streaming Delayed Price Updated: 4:00 PM EDT, May 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Press Releases about Pulse Biosciences, Inc - Common Stock

< Previous 1 2 3 4 5 6 7 Next >

Pulse Biosciences Reports Business Updates and First Quarter 2026 Financial Results

May 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Presents Positive Outcomes in Late-Breaking Updated Data from nPulse™ Cardiac Catheter System at Heart Rhythm 2026

April 25, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting

April 20, 2026

From Pulse Biosciences

Via Business Wire

Pulse Biosciences Enrolls First Patients in NANOPULSE-AF IDE Pivotal Clinical Study Evaluating nPulse™ Cardiac Catheter System for Atrial Fibrillation

April 07, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 25th Annual Needham Virtual Healthcare Conference

April 02, 2026

From Pulse Biosciences, Inc

Via Business Wire

Pulse Biosciences Announces Strategic Alignment to Accelerate Cardiac Catheter Program Following Exceptional Long-Term AFib Clinical Data

March 17, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces First Enrollments in Feasibility Study for the Treatment of Malignant Thyroid Tumors with nPulse™ Technology

March 12, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Clinical Data From nPulse™ Vybrance™ System First-In-Human Clinical Durability Study of Benign Thyroid Nodule Ablation

March 09, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the Oppenheimer 36th Annual Healthcare MedTech & Services Conference

March 05, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Vybrance™ System to be Featured in Multiple Presentations at the North American Society for Interventional Thyroidology Meeting

March 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 20, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 46th Annual TD Cowen Healthcare Conference

February 20, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2025 Financial Results

February 19, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

February 05, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Fourth Quarter & Full Year 2025 Financial Results Conference Call for February 19, 2026

February 04, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences’ nPulse™ Cardiac Catheter to Be Featured in Multiple Presentations at the AF Symposium

February 03, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Appoints Maria Sainz to its Board of Directors

January 09, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Selected to Present Late-Breaking Data from the nPulse Cardiac Catheter Study at the AF Symposium

January 06, 2026

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

December 29, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

December 19, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces FDA IDE Approval to Initiate its nPulse Cardiac Catheter Ablation System Study for the Treatment of Atrial Fibrillation

December 18, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Initiation of Research Collaboration for the Treatment of Benign and Malignant Thyroid Tumors with nPulse™ Technology

December 09, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

November 21, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences, Inc. Announces Participation in Upcoming Investor Conferences

November 06, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Reports Business Updates and Third Quarter 2025 Financial Results

November 05, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces First Enrollment in the NANOCLAMP AF Study

October 24, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Schedules Third Quarter 2025 Business Updates and Financial Results Conference Call for November 5, 2025

October 22, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 16, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Presentation of Late-Breaking Data From the nPulse™ Cardiac Surgical System First-in-Human Feasibility Study at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 10, 2025

From Pulse Biosciences, Inc.

Via Business Wire

Pulse Biosciences Announces Clinical Data Highlighting its nPulse™ Cardiac Surgical System to be Presented at the 39th European Association for Cardio-Thoracic Surgery Annual Meeting

October 07, 2025

From Pulse Biosciences

Via Business Wire

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.